nodes	percent_of_prediction	percent_of_DWPC	metapath
Mitotane—Retinal toxicity—Cisplatin—bone cancer	0.128	0.144	CcSEcCtD
Mitotane—Memory loss—Cisplatin—bone cancer	0.0263	0.0294	CcSEcCtD
Mitotane—Gastrointestinal toxicity—Methotrexate—bone cancer	0.0259	0.0289	CcSEcCtD
Mitotane—Gastrointestinal toxicity—Epirubicin—bone cancer	0.0242	0.0271	CcSEcCtD
Mitotane—Gastrointestinal toxicity—Doxorubicin—bone cancer	0.0224	0.025	CcSEcCtD
Mitotane—Cystitis haemorrhagic—Epirubicin—bone cancer	0.0198	0.0221	CcSEcCtD
Mitotane—Speech impairment NOS—Methotrexate—bone cancer	0.0194	0.0217	CcSEcCtD
Mitotane—Cystitis haemorrhagic—Doxorubicin—bone cancer	0.0183	0.0205	CcSEcCtD
Mitotane—CYP11B1—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.0131	0.138	CbGpPWpGaD
Mitotane—Polyneuropathy—Epirubicin—bone cancer	0.0122	0.0136	CcSEcCtD
Mitotane—Retinal disorder—Methotrexate—bone cancer	0.0119	0.0133	CcSEcCtD
Mitotane—Polyneuropathy—Doxorubicin—bone cancer	0.0113	0.0126	CcSEcCtD
Mitotane—CYP11A1—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.0112	0.118	CbGpPWpGaD
Mitotane—Infection—Carboplatin—bone cancer	0.00935	0.0105	CcSEcCtD
Mitotane—Liver injury—Cisplatin—bone cancer	0.00919	0.0103	CcSEcCtD
Mitotane—Dysarthria—Cisplatin—bone cancer	0.00818	0.00915	CcSEcCtD
Mitotane—Pain—Carboplatin—bone cancer	0.00805	0.009	CcSEcCtD
Mitotane—Hepatocellular injury—Cisplatin—bone cancer	0.00774	0.00865	CcSEcCtD
Mitotane—Mucosal inflammation—Methotrexate—bone cancer	0.00767	0.00858	CcSEcCtD
Mitotane—Body temperature increased—Carboplatin—bone cancer	0.00744	0.00832	CcSEcCtD
Mitotane—FDX1—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.0074	0.0778	CbGpPWpGaD
Mitotane—Mucosal inflammation—Epirubicin—bone cancer	0.00718	0.00803	CcSEcCtD
Mitotane—Mucosal inflammation—Doxorubicin—bone cancer	0.00664	0.00743	CcSEcCtD
Mitotane—Encephalopathy—Methotrexate—bone cancer	0.00661	0.0074	CcSEcCtD
Mitotane—Myasthenia—Epirubicin—bone cancer	0.00632	0.00707	CcSEcCtD
Mitotane—FDX1—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.006	0.0631	CbGpPWpGaD
Mitotane—Amnesia—Cisplatin—bone cancer	0.00598	0.00668	CcSEcCtD
Mitotane—Myasthenia—Doxorubicin—bone cancer	0.00585	0.00654	CcSEcCtD
Mitotane—CYP11B1—Metapathway biotransformation—CYP4V2—bone cancer	0.00566	0.0595	CbGpPWpGaD
Mitotane—Fungal infection—Methotrexate—bone cancer	0.0055	0.00615	CcSEcCtD
Mitotane—Dermatitis atopic—Epirubicin—bone cancer	0.00537	0.006	CcSEcCtD
Mitotane—Irritability—Cisplatin—bone cancer	0.00536	0.00599	CcSEcCtD
Mitotane—Albuminuria—Epirubicin—bone cancer	0.00532	0.00595	CcSEcCtD
Mitotane—Econazole—CYP3A4—bone cancer	0.00516	0.483	CrCbGaD
Mitotane—Fungal infection—Epirubicin—bone cancer	0.00515	0.00575	CcSEcCtD
Mitotane—Orthostatic hypotension—Cisplatin—bone cancer	0.00513	0.00574	CcSEcCtD
Mitotane—Breast disorder—Cisplatin—bone cancer	0.00508	0.00568	CcSEcCtD
Mitotane—Dermatitis atopic—Doxorubicin—bone cancer	0.00497	0.00555	CcSEcCtD
Mitotane—Speech disorder—Methotrexate—bone cancer	0.00494	0.00552	CcSEcCtD
Mitotane—Albuminuria—Doxorubicin—bone cancer	0.00492	0.00551	CcSEcCtD
Mitotane—CYP11A1—Metapathway biotransformation—CYP4V2—bone cancer	0.00484	0.0509	CbGpPWpGaD
Mitotane—Proteinuria—Methotrexate—bone cancer	0.00483	0.0054	CcSEcCtD
Mitotane—Protein urine present—Methotrexate—bone cancer	0.00477	0.00533	CcSEcCtD
Mitotane—Fungal infection—Doxorubicin—bone cancer	0.00476	0.00532	CcSEcCtD
Mitotane—Liver injury—Epirubicin—bone cancer	0.00472	0.00528	CcSEcCtD
Mitotane—Dysarthria—Methotrexate—bone cancer	0.00449	0.00502	CcSEcCtD
Mitotane—Hepatic enzyme increased—Methotrexate—bone cancer	0.00449	0.00502	CcSEcCtD
Mitotane—Liver injury—Doxorubicin—bone cancer	0.00437	0.00489	CcSEcCtD
Mitotane—Dyskinesia—Epirubicin—bone cancer	0.00423	0.00473	CcSEcCtD
Mitotane—Dysarthria—Epirubicin—bone cancer	0.0042	0.0047	CcSEcCtD
Mitotane—Hepatobiliary disease—Cisplatin—bone cancer	0.00409	0.00458	CcSEcCtD
Mitotane—Hepatocellular injury—Epirubicin—bone cancer	0.00397	0.00444	CcSEcCtD
Mitotane—Dyskinesia—Doxorubicin—bone cancer	0.00391	0.00437	CcSEcCtD
Mitotane—Dysarthria—Doxorubicin—bone cancer	0.00389	0.00435	CcSEcCtD
Mitotane—Salivary hypersecretion—Epirubicin—bone cancer	0.00386	0.00432	CcSEcCtD
Mitotane—Neoplasm—Methotrexate—bone cancer	0.00384	0.00429	CcSEcCtD
Mitotane—Urinary tract disorder—Cisplatin—bone cancer	0.00384	0.00429	CcSEcCtD
Mitotane—Connective tissue disorder—Cisplatin—bone cancer	0.00382	0.00427	CcSEcCtD
Mitotane—Urethral disorder—Cisplatin—bone cancer	0.00381	0.00426	CcSEcCtD
Mitotane—Gynaecomastia—Methotrexate—bone cancer	0.0038	0.00425	CcSEcCtD
Mitotane—Visual impairment—Cisplatin—bone cancer	0.00374	0.00419	CcSEcCtD
Mitotane—Hepatocellular injury—Doxorubicin—bone cancer	0.00368	0.00411	CcSEcCtD
Mitotane—Eye disorder—Cisplatin—bone cancer	0.00363	0.00406	CcSEcCtD
Mitotane—Flushing—Cisplatin—bone cancer	0.00361	0.00403	CcSEcCtD
Mitotane—Neoplasm—Epirubicin—bone cancer	0.00359	0.00402	CcSEcCtD
Mitotane—Salivary hypersecretion—Doxorubicin—bone cancer	0.00357	0.00399	CcSEcCtD
Mitotane—Mental disability—Epirubicin—bone cancer	0.00345	0.00386	CcSEcCtD
Mitotane—Malnutrition—Cisplatin—bone cancer	0.00338	0.00378	CcSEcCtD
Mitotane—Neoplasm—Doxorubicin—bone cancer	0.00332	0.00372	CcSEcCtD
Mitotane—Mental disability—Doxorubicin—bone cancer	0.00319	0.00357	CcSEcCtD
Mitotane—Vision blurred—Cisplatin—bone cancer	0.00319	0.00356	CcSEcCtD
Mitotane—FDX1—Biological oxidations—CYP3A4—bone cancer	0.00319	0.0335	CbGpPWpGaD
Mitotane—Tremor—Cisplatin—bone cancer	0.00317	0.00354	CcSEcCtD
Mitotane—Lethargy—Methotrexate—bone cancer	0.00315	0.00352	CcSEcCtD
Mitotane—Anaemia—Cisplatin—bone cancer	0.00313	0.0035	CcSEcCtD
Mitotane—Osteoarthritis—Methotrexate—bone cancer	0.00308	0.00345	CcSEcCtD
Mitotane—Carbinoxamine—CYP3A4—bone cancer	0.00299	0.28	CrCbGaD
Mitotane—Lethargy—Epirubicin—bone cancer	0.00294	0.00329	CcSEcCtD
Mitotane—Irritability—Methotrexate—bone cancer	0.00294	0.00329	CcSEcCtD
Mitotane—Ataxia—Methotrexate—bone cancer	0.0029	0.00324	CcSEcCtD
Mitotane—Diplopia—Epirubicin—bone cancer	0.00288	0.00323	CcSEcCtD
Mitotane—Osteoarthritis—Epirubicin—bone cancer	0.00288	0.00323	CcSEcCtD
Mitotane—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—bone cancer	0.00286	0.0032	CcSEcCtD
Mitotane—Breast disorder—Methotrexate—bone cancer	0.00279	0.00311	CcSEcCtD
Mitotane—Infection—Cisplatin—bone cancer	0.00274	0.00307	CcSEcCtD
Mitotane—FDX1—Biological oxidations—GSTP1—bone cancer	0.00272	0.0286	CbGpPWpGaD
Mitotane—Lethargy—Doxorubicin—bone cancer	0.00272	0.00305	CcSEcCtD
Mitotane—Ataxia—Epirubicin—bone cancer	0.00271	0.00303	CcSEcCtD
Mitotane—Nervous system disorder—Cisplatin—bone cancer	0.00271	0.00303	CcSEcCtD
Mitotane—Thrombocytopenia—Cisplatin—bone cancer	0.0027	0.00302	CcSEcCtD
Mitotane—Skin disorder—Cisplatin—bone cancer	0.00268	0.003	CcSEcCtD
Mitotane—Diplopia—Doxorubicin—bone cancer	0.00267	0.00298	CcSEcCtD
Mitotane—Osteoarthritis—Doxorubicin—bone cancer	0.00267	0.00298	CcSEcCtD
Mitotane—CYP11B1—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.00264	0.0277	CbGpPWpGaD
Mitotane—Orthostatic hypotension—Epirubicin—bone cancer	0.00263	0.00295	CcSEcCtD
Mitotane—Anorexia—Cisplatin—bone cancer	0.00263	0.00294	CcSEcCtD
Mitotane—Breast disorder—Epirubicin—bone cancer	0.00261	0.00291	CcSEcCtD
Mitotane—CYP11B1—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.0026	0.0273	CbGpPWpGaD
Mitotane—Hypotension—Cisplatin—bone cancer	0.00258	0.00288	CcSEcCtD
Mitotane—Muscular weakness—Epirubicin—bone cancer	0.00254	0.00284	CcSEcCtD
Mitotane—Chlorphenamine—CYP3A4—bone cancer	0.00254	0.238	CrCbGaD
Mitotane—Ataxia—Doxorubicin—bone cancer	0.00251	0.00281	CcSEcCtD
Mitotane—Neutropenia—Methotrexate—bone cancer	0.00249	0.00279	CcSEcCtD
Mitotane—Paraesthesia—Cisplatin—bone cancer	0.00248	0.00277	CcSEcCtD
Mitotane—Orthostatic hypotension—Doxorubicin—bone cancer	0.00244	0.00273	CcSEcCtD
Mitotane—Breast disorder—Doxorubicin—bone cancer	0.00241	0.0027	CcSEcCtD
Mitotane—Decreased appetite—Cisplatin—bone cancer	0.0024	0.00268	CcSEcCtD
Mitotane—Gastrointestinal disorder—Cisplatin—bone cancer	0.00238	0.00267	CcSEcCtD
Mitotane—Drowsiness—Methotrexate—bone cancer	0.00238	0.00266	CcSEcCtD
Mitotane—Infestation—Methotrexate—bone cancer	0.00238	0.00266	CcSEcCtD
Mitotane—Infestation NOS—Methotrexate—bone cancer	0.00238	0.00266	CcSEcCtD
Mitotane—Pain—Cisplatin—bone cancer	0.00236	0.00264	CcSEcCtD
Mitotane—Muscular weakness—Doxorubicin—bone cancer	0.00235	0.00263	CcSEcCtD
Mitotane—Neutropenia—Epirubicin—bone cancer	0.00233	0.00261	CcSEcCtD
Mitotane—Feeling abnormal—Cisplatin—bone cancer	0.00227	0.00254	CcSEcCtD
Mitotane—Haematuria—Methotrexate—bone cancer	0.00226	0.00253	CcSEcCtD
Mitotane—CYP11A1—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.00225	0.0237	CbGpPWpGaD
Mitotane—Hepatobiliary disease—Methotrexate—bone cancer	0.00225	0.00251	CcSEcCtD
Mitotane—CYP11A1—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.00222	0.0234	CbGpPWpGaD
Mitotane—Infestation—Epirubicin—bone cancer	0.00222	0.00249	CcSEcCtD
Mitotane—Infestation NOS—Epirubicin—bone cancer	0.00222	0.00249	CcSEcCtD
Mitotane—Drowsiness—Epirubicin—bone cancer	0.00222	0.00249	CcSEcCtD
Mitotane—Body temperature increased—Cisplatin—bone cancer	0.00218	0.00244	CcSEcCtD
Mitotane—Neutropenia—Doxorubicin—bone cancer	0.00216	0.00241	CcSEcCtD
Mitotane—CYP11B1—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.00214	0.0225	CbGpPWpGaD
Mitotane—Hepatitis—Methotrexate—bone cancer	0.00213	0.00238	CcSEcCtD
Mitotane—Haematuria—Epirubicin—bone cancer	0.00212	0.00237	CcSEcCtD
Mitotane—Urinary tract disorder—Methotrexate—bone cancer	0.00211	0.00235	CcSEcCtD
Mitotane—Hepatobiliary disease—Epirubicin—bone cancer	0.0021	0.00235	CcSEcCtD
Mitotane—Urethral disorder—Methotrexate—bone cancer	0.00209	0.00234	CcSEcCtD
Mitotane—CYP11B1—Corticotropin-releasing hormone—GNA11—bone cancer	0.00206	0.0217	CbGpPWpGaD
Mitotane—Drowsiness—Doxorubicin—bone cancer	0.00206	0.0023	CcSEcCtD
Mitotane—Infestation NOS—Doxorubicin—bone cancer	0.00206	0.0023	CcSEcCtD
Mitotane—Infestation—Doxorubicin—bone cancer	0.00206	0.0023	CcSEcCtD
Mitotane—Visual impairment—Methotrexate—bone cancer	0.00205	0.0023	CcSEcCtD
Mitotane—Hypersensitivity—Cisplatin—bone cancer	0.00203	0.00227	CcSEcCtD
Mitotane—Hepatitis—Epirubicin—bone cancer	0.002	0.00223	CcSEcCtD
Mitotane—Eye disorder—Methotrexate—bone cancer	0.00199	0.00223	CcSEcCtD
Mitotane—Asthenia—Cisplatin—bone cancer	0.00198	0.00221	CcSEcCtD
Mitotane—Urinary tract disorder—Epirubicin—bone cancer	0.00197	0.0022	CcSEcCtD
Mitotane—Haematuria—Doxorubicin—bone cancer	0.00196	0.00219	CcSEcCtD
Mitotane—Connective tissue disorder—Epirubicin—bone cancer	0.00196	0.00219	CcSEcCtD
Mitotane—Urethral disorder—Epirubicin—bone cancer	0.00196	0.00219	CcSEcCtD
Mitotane—Hepatobiliary disease—Doxorubicin—bone cancer	0.00194	0.00218	CcSEcCtD
Mitotane—Angiopathy—Methotrexate—bone cancer	0.00193	0.00216	CcSEcCtD
Mitotane—Visual impairment—Epirubicin—bone cancer	0.00192	0.00215	CcSEcCtD
Mitotane—FDX1—Metabolism—NDUFA12—bone cancer	0.00191	0.0201	CbGpPWpGaD
Mitotane—Diarrhoea—Cisplatin—bone cancer	0.00189	0.00211	CcSEcCtD
Mitotane—Mental disorder—Methotrexate—bone cancer	0.00187	0.00209	CcSEcCtD
Mitotane—Eye disorder—Epirubicin—bone cancer	0.00186	0.00209	CcSEcCtD
Mitotane—Malnutrition—Methotrexate—bone cancer	0.00186	0.00208	CcSEcCtD
Mitotane—Flushing—Epirubicin—bone cancer	0.00185	0.00207	CcSEcCtD
Mitotane—Hepatitis—Doxorubicin—bone cancer	0.00185	0.00206	CcSEcCtD
Mitotane—CYP11A1—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.00183	0.0192	CbGpPWpGaD
Mitotane—Urinary tract disorder—Doxorubicin—bone cancer	0.00182	0.00204	CcSEcCtD
Mitotane—Dysgeusia—Methotrexate—bone cancer	0.00182	0.00203	CcSEcCtD
Mitotane—Connective tissue disorder—Doxorubicin—bone cancer	0.00181	0.00203	CcSEcCtD
Mitotane—Angiopathy—Epirubicin—bone cancer	0.00181	0.00202	CcSEcCtD
Mitotane—Urethral disorder—Doxorubicin—bone cancer	0.00181	0.00202	CcSEcCtD
Mitotane—Visual impairment—Doxorubicin—bone cancer	0.00178	0.00199	CcSEcCtD
Mitotane—CYP11A1—Corticotropin-releasing hormone—GNA11—bone cancer	0.00177	0.0186	CbGpPWpGaD
Mitotane—Vomiting—Cisplatin—bone cancer	0.00176	0.00196	CcSEcCtD
Mitotane—Vision blurred—Methotrexate—bone cancer	0.00175	0.00196	CcSEcCtD
Mitotane—Mental disorder—Epirubicin—bone cancer	0.00175	0.00195	CcSEcCtD
Mitotane—Rash—Cisplatin—bone cancer	0.00174	0.00195	CcSEcCtD
Mitotane—CYP11A1—Prostaglandin Synthesis and Regulation—PTGS2—bone cancer	0.00174	0.0183	CbGpPWpGaD
Mitotane—Dermatitis—Cisplatin—bone cancer	0.00174	0.00194	CcSEcCtD
Mitotane—Malnutrition—Epirubicin—bone cancer	0.00174	0.00194	CcSEcCtD
Mitotane—Eye disorder—Doxorubicin—bone cancer	0.00173	0.00193	CcSEcCtD
Mitotane—Anaemia—Methotrexate—bone cancer	0.00172	0.00192	CcSEcCtD
Mitotane—Flushing—Doxorubicin—bone cancer	0.00171	0.00192	CcSEcCtD
Mitotane—Dysgeusia—Epirubicin—bone cancer	0.0017	0.0019	CcSEcCtD
Mitotane—Angiopathy—Doxorubicin—bone cancer	0.00168	0.00187	CcSEcCtD
Mitotane—Vertigo—Methotrexate—bone cancer	0.00167	0.00186	CcSEcCtD
Mitotane—Nausea—Cisplatin—bone cancer	0.00164	0.00183	CcSEcCtD
Mitotane—Vision blurred—Epirubicin—bone cancer	0.00164	0.00183	CcSEcCtD
Mitotane—Mental disorder—Doxorubicin—bone cancer	0.00162	0.00181	CcSEcCtD
Mitotane—Malnutrition—Doxorubicin—bone cancer	0.00161	0.0018	CcSEcCtD
Mitotane—Anaemia—Epirubicin—bone cancer	0.00161	0.0018	CcSEcCtD
Mitotane—FDX1—Metabolism—NT5C3A—bone cancer	0.00158	0.0166	CbGpPWpGaD
Mitotane—Dysgeusia—Doxorubicin—bone cancer	0.00157	0.00176	CcSEcCtD
Mitotane—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—bone cancer	0.00157	0.00175	CcSEcCtD
Mitotane—Vertigo—Epirubicin—bone cancer	0.00156	0.00175	CcSEcCtD
Mitotane—Confusional state—Methotrexate—bone cancer	0.00153	0.00171	CcSEcCtD
Mitotane—Vision blurred—Doxorubicin—bone cancer	0.00151	0.00169	CcSEcCtD
Mitotane—Infection—Methotrexate—bone cancer	0.0015	0.00168	CcSEcCtD
Mitotane—Hypertension—Epirubicin—bone cancer	0.0015	0.00168	CcSEcCtD
Mitotane—Nervous system disorder—Methotrexate—bone cancer	0.00149	0.00166	CcSEcCtD
Mitotane—Anaemia—Doxorubicin—bone cancer	0.00149	0.00166	CcSEcCtD
Mitotane—Thrombocytopenia—Methotrexate—bone cancer	0.00148	0.00166	CcSEcCtD
Mitotane—Skin disorder—Methotrexate—bone cancer	0.00147	0.00165	CcSEcCtD
Mitotane—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—bone cancer	0.00147	0.00164	CcSEcCtD
Mitotane—Vertigo—Doxorubicin—bone cancer	0.00144	0.00161	CcSEcCtD
Mitotane—Anorexia—Methotrexate—bone cancer	0.00144	0.00161	CcSEcCtD
Mitotane—Confusional state—Epirubicin—bone cancer	0.00143	0.0016	CcSEcCtD
Mitotane—Hypotension—Methotrexate—bone cancer	0.00142	0.00158	CcSEcCtD
Mitotane—Infection—Epirubicin—bone cancer	0.00141	0.00157	CcSEcCtD
Mitotane—Shock—Epirubicin—bone cancer	0.00139	0.00156	CcSEcCtD
Mitotane—Nervous system disorder—Epirubicin—bone cancer	0.00139	0.00155	CcSEcCtD
Mitotane—Thrombocytopenia—Epirubicin—bone cancer	0.00139	0.00155	CcSEcCtD
Mitotane—Hypertension—Doxorubicin—bone cancer	0.00139	0.00155	CcSEcCtD
Mitotane—Skin disorder—Epirubicin—bone cancer	0.00138	0.00154	CcSEcCtD
Mitotane—Paraesthesia—Methotrexate—bone cancer	0.00136	0.00152	CcSEcCtD
Mitotane—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—bone cancer	0.00136	0.00152	CcSEcCtD
Mitotane—Anorexia—Epirubicin—bone cancer	0.00135	0.00151	CcSEcCtD
Mitotane—Somnolence—Methotrexate—bone cancer	0.00135	0.00151	CcSEcCtD
Mitotane—Dyspepsia—Methotrexate—bone cancer	0.00133	0.00149	CcSEcCtD
Mitotane—Hypotension—Epirubicin—bone cancer	0.00132	0.00148	CcSEcCtD
Mitotane—Confusional state—Doxorubicin—bone cancer	0.00132	0.00148	CcSEcCtD
Mitotane—Decreased appetite—Methotrexate—bone cancer	0.00132	0.00147	CcSEcCtD
Mitotane—Gastrointestinal disorder—Methotrexate—bone cancer	0.00131	0.00146	CcSEcCtD
Mitotane—Infection—Doxorubicin—bone cancer	0.0013	0.00146	CcSEcCtD
Mitotane—Pain—Methotrexate—bone cancer	0.0013	0.00145	CcSEcCtD
Mitotane—Shock—Doxorubicin—bone cancer	0.00129	0.00144	CcSEcCtD
Mitotane—Nervous system disorder—Doxorubicin—bone cancer	0.00129	0.00144	CcSEcCtD
Mitotane—Thrombocytopenia—Doxorubicin—bone cancer	0.00128	0.00144	CcSEcCtD
Mitotane—Skin disorder—Doxorubicin—bone cancer	0.00127	0.00142	CcSEcCtD
Mitotane—Paraesthesia—Epirubicin—bone cancer	0.00127	0.00142	CcSEcCtD
Mitotane—Somnolence—Epirubicin—bone cancer	0.00126	0.00141	CcSEcCtD
Mitotane—Anorexia—Doxorubicin—bone cancer	0.00125	0.0014	CcSEcCtD
Mitotane—Feeling abnormal—Methotrexate—bone cancer	0.00125	0.0014	CcSEcCtD
Mitotane—Dyspepsia—Epirubicin—bone cancer	0.00125	0.0014	CcSEcCtD
Mitotane—Decreased appetite—Epirubicin—bone cancer	0.00123	0.00138	CcSEcCtD
Mitotane—Hypotension—Doxorubicin—bone cancer	0.00123	0.00137	CcSEcCtD
Mitotane—Gastrointestinal disorder—Epirubicin—bone cancer	0.00122	0.00137	CcSEcCtD
Mitotane—Pain—Epirubicin—bone cancer	0.00121	0.00136	CcSEcCtD
Mitotane—Body temperature increased—Methotrexate—bone cancer	0.0012	0.00134	CcSEcCtD
Mitotane—Paraesthesia—Doxorubicin—bone cancer	0.00118	0.00132	CcSEcCtD
Mitotane—Feeling abnormal—Epirubicin—bone cancer	0.00117	0.00131	CcSEcCtD
Mitotane—Somnolence—Doxorubicin—bone cancer	0.00117	0.0013	CcSEcCtD
Mitotane—Dyspepsia—Doxorubicin—bone cancer	0.00115	0.00129	CcSEcCtD
Mitotane—Decreased appetite—Doxorubicin—bone cancer	0.00114	0.00128	CcSEcCtD
Mitotane—CYP11B1—Biological oxidations—CYP3A4—bone cancer	0.00113	0.0119	CbGpPWpGaD
Mitotane—Gastrointestinal disorder—Doxorubicin—bone cancer	0.00113	0.00127	CcSEcCtD
Mitotane—Pain—Doxorubicin—bone cancer	0.00112	0.00125	CcSEcCtD
Mitotane—Body temperature increased—Epirubicin—bone cancer	0.00112	0.00125	CcSEcCtD
Mitotane—CYP11B1—Metapathway biotransformation—CYP3A4—bone cancer	0.00112	0.0118	CbGpPWpGaD
Mitotane—Hypersensitivity—Methotrexate—bone cancer	0.00112	0.00125	CcSEcCtD
Mitotane—Asthenia—Methotrexate—bone cancer	0.00109	0.00122	CcSEcCtD
Mitotane—Feeling abnormal—Doxorubicin—bone cancer	0.00108	0.00121	CcSEcCtD
Mitotane—Hypersensitivity—Epirubicin—bone cancer	0.00104	0.00117	CcSEcCtD
Mitotane—Body temperature increased—Doxorubicin—bone cancer	0.00104	0.00116	CcSEcCtD
Mitotane—Diarrhoea—Methotrexate—bone cancer	0.00104	0.00116	CcSEcCtD
Mitotane—CYP11B1—Corticotropin-releasing hormone—BRAF—bone cancer	0.00103	0.0108	CbGpPWpGaD
Mitotane—Asthenia—Epirubicin—bone cancer	0.00102	0.00114	CcSEcCtD
Mitotane—Dizziness—Methotrexate—bone cancer	0.001	0.00112	CcSEcCtD
Mitotane—CYP11A1—Biological oxidations—CYP3A4—bone cancer	0.000971	0.0102	CbGpPWpGaD
Mitotane—CYP11B1—Biological oxidations—GSTP1—bone cancer	0.000971	0.0102	CbGpPWpGaD
Mitotane—Diarrhoea—Epirubicin—bone cancer	0.00097	0.00108	CcSEcCtD
Mitotane—Hypersensitivity—Doxorubicin—bone cancer	0.000966	0.00108	CcSEcCtD
Mitotane—Vomiting—Methotrexate—bone cancer	0.000963	0.00108	CcSEcCtD
Mitotane—CYP11A1—Metapathway biotransformation—CYP3A4—bone cancer	0.000957	0.0101	CbGpPWpGaD
Mitotane—CYP11B1—Metapathway biotransformation—GSTP1—bone cancer	0.000957	0.0101	CbGpPWpGaD
Mitotane—Rash—Methotrexate—bone cancer	0.000955	0.00107	CcSEcCtD
Mitotane—Dermatitis—Methotrexate—bone cancer	0.000954	0.00107	CcSEcCtD
Mitotane—Headache—Methotrexate—bone cancer	0.000949	0.00106	CcSEcCtD
Mitotane—Asthenia—Doxorubicin—bone cancer	0.000941	0.00105	CcSEcCtD
Mitotane—Dizziness—Epirubicin—bone cancer	0.000937	0.00105	CcSEcCtD
Mitotane—Vomiting—Epirubicin—bone cancer	0.000901	0.00101	CcSEcCtD
Mitotane—Nausea—Methotrexate—bone cancer	0.0009	0.00101	CcSEcCtD
Mitotane—Diarrhoea—Doxorubicin—bone cancer	0.000897	0.001	CcSEcCtD
Mitotane—Rash—Epirubicin—bone cancer	0.000894	0.001	CcSEcCtD
Mitotane—Dermatitis—Epirubicin—bone cancer	0.000893	0.000999	CcSEcCtD
Mitotane—Headache—Epirubicin—bone cancer	0.000888	0.000993	CcSEcCtD
Mitotane—CYP11A1—Corticotropin-releasing hormone—BRAF—bone cancer	0.000878	0.00924	CbGpPWpGaD
Mitotane—Dizziness—Doxorubicin—bone cancer	0.000867	0.00097	CcSEcCtD
Mitotane—Nausea—Epirubicin—bone cancer	0.000842	0.000942	CcSEcCtD
Mitotane—Vomiting—Doxorubicin—bone cancer	0.000834	0.000933	CcSEcCtD
Mitotane—CYP11A1—Biological oxidations—GSTP1—bone cancer	0.00083	0.00873	CbGpPWpGaD
Mitotane—Rash—Doxorubicin—bone cancer	0.000827	0.000925	CcSEcCtD
Mitotane—Dermatitis—Doxorubicin—bone cancer	0.000826	0.000924	CcSEcCtD
Mitotane—Headache—Doxorubicin—bone cancer	0.000822	0.000919	CcSEcCtD
Mitotane—CYP11A1—Metapathway biotransformation—GSTP1—bone cancer	0.000819	0.00861	CbGpPWpGaD
Mitotane—Nausea—Doxorubicin—bone cancer	0.000779	0.000871	CcSEcCtD
Mitotane—FDX1—Metabolism—ENO2—bone cancer	0.000693	0.00729	CbGpPWpGaD
Mitotane—CYP11B1—Metabolism—NDUFA12—bone cancer	0.00068	0.00715	CbGpPWpGaD
Mitotane—FDX1—Metabolism—DHFR—bone cancer	0.000643	0.00676	CbGpPWpGaD
Mitotane—FDX1—Metabolism—GNA11—bone cancer	0.000601	0.00632	CbGpPWpGaD
Mitotane—CYP11A1—Metabolism—NDUFA12—bone cancer	0.000582	0.00612	CbGpPWpGaD
Mitotane—CYP11B1—Metabolism—NT5C3A—bone cancer	0.000564	0.00593	CbGpPWpGaD
Mitotane—FDX1—Metabolism—CYP3A4—bone cancer	0.000545	0.00573	CbGpPWpGaD
Mitotane—FDX1—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	0.000542	0.0057	CbGpPWpGaD
Mitotane—CYP11A1—Metabolism—NT5C3A—bone cancer	0.000482	0.00507	CbGpPWpGaD
Mitotane—FDX1—Metabolism—GSTP1—bone cancer	0.000466	0.0049	CbGpPWpGaD
Mitotane—CYP11B1—Metabolism—ENO2—bone cancer	0.000247	0.0026	CbGpPWpGaD
Mitotane—FDX1—Metabolism—PTGS2—bone cancer	0.000241	0.00254	CbGpPWpGaD
Mitotane—CYP11B1—Metabolism—DHFR—bone cancer	0.000229	0.00241	CbGpPWpGaD
Mitotane—CYP11B1—Metabolism—GNA11—bone cancer	0.000214	0.00225	CbGpPWpGaD
Mitotane—CYP11A1—Metabolism—ENO2—bone cancer	0.000211	0.00222	CbGpPWpGaD
Mitotane—CYP11A1—Metabolism—DHFR—bone cancer	0.000196	0.00206	CbGpPWpGaD
Mitotane—CYP11B1—Metabolism—CYP3A4—bone cancer	0.000194	0.00204	CbGpPWpGaD
Mitotane—CYP11B1—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	0.000193	0.00203	CbGpPWpGaD
Mitotane—CYP11A1—Metabolism—GNA11—bone cancer	0.000183	0.00193	CbGpPWpGaD
Mitotane—CYP11A1—Metabolism—CYP3A4—bone cancer	0.000166	0.00175	CbGpPWpGaD
Mitotane—CYP11B1—Metabolism—GSTP1—bone cancer	0.000166	0.00175	CbGpPWpGaD
Mitotane—CYP11A1—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	0.000165	0.00174	CbGpPWpGaD
Mitotane—CYP11A1—Metabolism—GSTP1—bone cancer	0.000142	0.00149	CbGpPWpGaD
Mitotane—CYP11B1—Metabolism—PTGS2—bone cancer	8.6e-05	0.000904	CbGpPWpGaD
Mitotane—CYP11A1—Metabolism—PTGS2—bone cancer	7.36e-05	0.000774	CbGpPWpGaD
